| Exclusion Criteria: | 1) Diagnosis of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, or other hematologic malignancy
2) Any prior allogeneic transplant
3) Prior autologous bone marrow or peripheral stem cell transplant less than 3 months prior to study enrollment
4) Substantial radiotherapy to the bone marrow within 6 weeks prior to enrollment (or within 6 months prior to enrollment if prior radiotherapy to the craniospinal axis or to at least 59% of the pelvis was received; within 2 weeks prior to enrollment if local palliative radiotherapy was received)
5) Prior use of any monoclonal antibodies targeting the EGFr. Subjects who have received prior tyrosine kinase inhibitors such as gefitinib (IressaŽ) or erlotinib (TarcevaŽ) are eligible.
6) Immunotherapy, radiotherapy, or chemotherapy </= 2 weeks prior to enrollment (</= 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and </= 6 weeks from prior antibody therapy)
7) Requirement to receive concurrent chemotherapy, immunotherapy, radiotherapy (except for pain control), or any other investigational drug while on this study
8) Prior seizures < 3 months prior to enrollment. Subjects with a history of seizure disorders >/= 3 months prior to enrollment must be seizure free and on stable anticonvulsant medication(s) for >/= 3 months prior to enrollment.
9) Presence of a serious uncontrolled medical disorder
10) Dementia, altered mental status, or any other medical condition or disorder that would prohibit the understanding or rendering of assent (if applicable), or ability to comply with study procedures
11) Major surgery </= 28 days prior to enrollment
12) Known or suspected history of interstitial lung disease (eg, pneumonitis or pulmonary fibrosis)
13) Active inflammatory bowel disease or other bowel disease causing chronic diarrhea (defined as >/= CTC grade 2 [CTCAE version 3.0])
14) Known positive test for human immunodeficiency virus infection, hepatitis C virus infection, acute or chronic hepatitis B infection, or any co-morbid disease that would increase risk of toxicity
15) Females of childbearing potential not using adequate contraception precautions for the duration of the study treatment and for 2 months after the last administration of investigational product
16) Pregnant or breast-feeding, or planning to become pregnant during study treatment and within 2 months after the last administration of investigational product
17) Received investigational therapy or procedure </= 30 days prior to enrollment |